Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Relation Between Body Composition, Systemic Inflammatory Response, and Clinical Outcomes in Patients Admitted to an Urban Teaching Hospital with COVID-19

Josh McGovern,1 Ross Dolan,1 Conor Richards,2 Barry J Laird,1 Donald C McMillan,1 and Donogh Maguire4

1Academic Unit of Surgery, School of Medicine, University of Glasgow, New Lister Building, Royal Infirmary, Glasgow, United Kingdom; 2School of Medicine, University of Glasgow, Glasgow, United Kingdom; 3Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom; and 4Emergency Department, Glasgow Royal Infirmary, Glasgow, United Kingdom

ABSTRACT

Background: COVID-19 has been associated with cases of severe respiratory illness, admissions to intensive therapy units (ITUs), and high mortality rates.

Objectives: The aim of the present study was to examine the relation between computed tomography-body composition (CT-BC) measurements, systemic inflammation, and clinical outcomes in those with COVID-19.

Methods: Patients who presented to our institution between March 17 and May 1, 2020, with a positive PCR test for COVID-19 or characteristic radiological changes, were assessed for inclusion. Data collected included general demographic details, clinicopathological variables, poGPS, NLR, CT-BC measurements, and clinical outcomes including ITU admission and 30-d mortality, of those admitted.

Results: Sixty-three patients met the study inclusion criteria. Forty-two patients (67%) were aged ≥70 y, 30 (47.6%) were male and 34.9% (n = 22) had a poGPS ≥1. ITU admission was significantly associated with a high VFA (P < 0.05). Thirty-day mortality was associated with high VFA (P < 0.05) and low SMI (P < 0.05).

Conclusions: Sarcopenia in the presence of obesity was associated with clinical outcomes including greater 30-d mortality. J Nutr 2021;151:2236–2244.

Keywords: body composition, obesity, sarcopenia, CT, COVID-19

Introduction

The WHO declared the outbreak of novel coronavirus 19 (COVID-19) a global pandemic on March 11, 2020 (1). Despite an expansion in resources for testing and contact tracing, hospital admissions and death rates within the United Kingdom remained high (2). Since first identified, COVID-19 has been associated with cases of severe respiratory illness, often requiring hospitalization and in some cases admission to an intensive therapy unit (ITU), as well as high mortality rates (3). With the potential for health services to become overwhelmed due to finite resources such as ventilators and level 3 ITU beds available and staffed, factors that aid in prognostication are essential to triage those admitted with COVID-19. This could provide an invaluable insight in the fight against the current global pandemic.

A marked systemic inflammatory response has been identified as one of the signs of severe COVID-19 (4). Recent studies have shown that severe systemic inflammation is associated with mortality in those with COVID-19, suggesting that it can have a role in determining prognosis. Furthermore, obesity, as measured by BMI (5) and visceral fat area (VFA) (6, 7) derived from computed tomography (CT) image analysis, has been reported to have a detrimental impact on clinical outcomes in those with COVID-19. The relation between CT-derived measures of body composition including low skeletal muscle mass and density, systemic inflammation, and outcomes in those with cancer have previously been reported (8, 9). However, to date, there have been no studies exploring the relation between systemic inflammation, CT-derived body composition (CT-BC) measurements, and clinical outcomes in those with COVID-19.

References...

© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Therefore, the aim of the present study was to examine the relation between CT-BC measurements, systemic inflammatory status, and clinical outcomes in those with COVID-19.

Methods

Data were collected on patients who attended the Emergency Department (ED) and Acute Assessment Unit (AAU) at Glasgow Royal Infirmary (GRI), Glasgow, United Kingdom, during the initial 7-wk period of the COVID-19 pandemic in Glasgow city (March 17, 2020 to May 1, 2020). GRI is a university teaching hospital, serving an urban population with a high burden of socioeconomic deprivation. In line with UK National Health Service (NHS) policy, this study was approved by the NHS Greater Glasgow and Clyde Caldicott guardian. The study protocol (GN20AE307) was approved by the North West England—Preston research ethics committee (20/NW/0336) and registered with clinicaltrials.gov (NCT04484545).

Patients displaying clinical signs or symptoms consistent with possible COVID-19 (as defined by Health Protection Scotland) (10), at the time of presentation to the ED and AAU, were assessed for inclusion in the study. Patients were then further analyzed to identify those with either a positive PCR test or radiological changes characteristic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reported on chest X-ray or CT thorax, by a board-certified radiologist. Finally, patients with confirmed COVID-19 were then assessed to identify those who had CT imaging within 3 mo of the diagnosis (see Figure 1). Eligible CT imaging required cross-sectional scanning at the level of the third lumbar vertebra. Patients whose scans were taken outwith this period were excluded from the study. Furthermore, scans with significant movement artefact or missing region of interest were not considered for inclusion.

Routine demographic details, clinical observations, hematological and biochemical laboratory results, as well as clinical outcome data were recorded. Age, sex, ethnicity, BMI, and diagnostic modality confirming COVID-19 as well as date of diagnosis were minimal inclusion criteria. Age categories were grouped to <70 y or ≥70 y. Social deprivation was defined by the Scottish Indices of Multiple Deprivation 2019 based on individuals’ home postcodes. Ethnicity was classified as white or other ethnic group. Admission serum C-reactive protein (CRP), albumin, and differential blood cell counts were categorized using local reference intervals. Neutrophil:lymphocyte ratio (NLR) (11) and the perioperative Glasgow Prognostic Score (poGPS) (12) were used to assess systemic inflammation. For this study, thresholds of NLR <3, 3–5, >5 were chosen and categorized as “mild,” “moderate,” and “severe” systemic inflammatory response, respectively. poGPS values were grouped into “noninflamed” (i.e., poGPS = 0) and “inflamed” (i.e., poGPS = 1 or 2) cohorts. Primary outcomes measured were intensive care admission and mortality within 30 d of diagnosis with COVID-19.

Body composition analysis

Each CT image was individually analyzed using ImageJ—a free to download, Java-based program developed by NIH [NIH ImageJ version 1.47, http://rsbweb.nih.gov/ij/) shown to provide reliable measurements (13). Body composition measurements derived from the CT image slice at L3 included total fat area (TFA), visceral fat area (VFA), and skeletal muscle area (SMA). Attenuation thresholds were from −190 to +30 Hounsfield units (HU) for fat and −29 to +150 HU for muscle. The TFA was quantified by depicting the outer contours of the abdominal wall, compared with the inner contour of the psoas and abdominal wall muscles for VFA. Similarly, SMA was measured by manually delineating muscle areas including the quadratus lumborum, psoas, rectus abdominus, and erector spinae muscles, and the internal transverse and external oblique muscle groups. Skeletal muscle radiodensity (SMD) was calculated (in Hounsfield units) as the mean of the measured muscle area used to calculate SMA. Subcutaneous fat area (SFA) was calculated by subtraction of the VFA from TFA. SFA and SMA measurements were then normalized by division of the patient’s height in meters squared to generate a subcutaneous fat index (SFI: centimeters squared/meters squared) and skeletal muscle index (SMI: centimeters squared/meters squared). These indices were then compared with established thresholds for body composition status (see Table 1).

Statistical analysis

Demographic data, CT-BC measurements, poGPS, and NLR were presented as categorical variables. Categorical variables were analyzed using χ² test for linear-by-linear association.
Missing data were excluded from analysis on a variable-by-variable basis. Two-tailed \( P \) values < 0.05 were considered statistically significant. Statistical analysis was performed using SPSS software version 25.0 (SPSS Inc.).

### Results

Of the 224 patients admitted to GRI during the study period, 63 met the study inclusion criteria. The clinicopathological characteristics at presentation are shown in Table 2. Forty-two patients (67%) were aged \( \geq 70 \) y. Thirty (48%) participants were male. The majority of patients were of white, Scottish ethnicity (94%). With the exception of hypertension, which was present in 34 (53%) individuals included, the majority of patients had no history of comorbid disease—heart failure (13%), type 2 diabetes (28%), liver disease (10%), chronic renal failure (18%), asthma (21%), and chronic obstructive pulmonary disease (22%). Of those included, 11 (18%) patients had active cancer. Of those admitted, 16% (\( n = 10 \)) were current smokers, with 28 (44%) patients reporting a past history of smoking.

The median BMI was 26.5 kg/m\(^2\), with 49% (\( n = 31 \)) of patients having a BMI \( \geq 25 \), and 24% (\( n = 15 \)) having a BMI \( \geq 30 \). A severe systemic inflammatory response (CRP \( \geq 80 \) g/L) was present in almost half of individuals studied (49%) (\( n = 31 \)), and a very severe systemic inflammatory response (CRP \( \geq 150 \) g/L) was present in 14 (22%). A serum albumin \(< 35 \) mg/L was present in 84% (\( n = 53 \)) of individuals. Seventeen (27%) patients had a poGPS score of 1, and 5 (8%) had a poGPS of 2. An NLR of 3–5 was reported in 22% (\( n = 14 \)) of individuals studied, with 39 (62%) having an NLR > 5, indicating moderate and severe inflammation, respectively.

Of the patients with imaging deemed to be of sufficient, analyzable standard for inclusion within the study, 48 (76%) had a CT thorax, abdomen, and pelvis, with 24% (\( n = 13 \)) having a CT abdomen and pelvis only. CT-BC measurements included were VFA, SFI, SMI, and SMD using predefined thresholds. CT-BC analysis results are shown in Table 1. A high VFA was present in 67% (\( n = 42 \)) of patients. VFA was significantly associated with BMI (\( P < 0.01 \)), smoking status (\( P < 0.01 \)), active cancer (\( P < 0.01 \)), ITU admission (\( P < 0.05 \)), and 30-d mortality (\( P < 0.01 \); Table 3). A high SFI was present in a greater number of patients: 75% (\( n = 47 \)). SFI was associated with gender (\( P \leq 0.05 \)), age (\( P < 0.01 \)), BMI (\( P < 0.01 \)), chronic renal failure (\( P < 0.05 \)), asthma (\( P < 0.05 \)), and active cancer (\( P < 0.05 \); Table 4). SMI and SMD were assessed using thresholds defined by Martin et al. (15). A low SMI was present in 62% (\( n = 39 \)) of patients, and a low SMD in 81% (\( n = 51 \)). Low SMI was associated with BMI (\( P < 0.01 \)) and 30-d mortality (\( P < 0.05 \); Table 5). A low SMD was associated with age (\( P < 0.05 \); Table 6).

Of the patients included, 3 (5%) had an ITU admission. Two patients were admitted directly to ITU from the ED, with 1 requiring escalation to a level 3 bed from ward-level care during admission. ITU admission was significantly associated with a high VFA (\( P < 0.05 \); Table 3). Thirty-day mortality was associated with high VFA (\( P < 0.05 \)) and low SMI (\( P < 0.05 \); see Tables 3 and 5, respectively).

### Discussion

To our knowledge, this is the first study to explore the relation between CT-BC measurements, systemic inflammation, and outcomes in patients with COVID-19. The patients included were mainly elderly, were of white ethnicity, were systemically inflamed, overweight with subcutaneous and visceral obesity, and had sarcopenia using standard thresholds. Furthermore, sarcopenia in the presence of obesity was associated with clinical outcomes including greater 30-d mortality. Therefore, it would appear that body composition could have an important role in predicting clinical outcome in patients presenting with COVID-19. Further large-scale studies are warranted to establish the prognostic role of body composition in these patients.

Numerous studies have suggested that obesity, as measured by BMI, is associated with poorer outcomes in patients with COVID-19 (5, 17). However, BMI reflects both fat and muscle mass in the body and therefore it is not clear whether such increased risk is due to high fat mass, low muscle mass, or both. In the present study visceral obesity appeared to be associated with a lower 30-d mortality whereas sarcopenia was associated with a higher 30-d mortality. The basis of this divergence of body composition components and clinical outcome is not clear. However, a low muscle mass against a background of an acute (18) or chronic inflammatory state has long been recognized to be associated with poor clinical outcomes (19). Irrespective, it will be important to carry out further body composition studies in patients with COVID-19.

Sarcopenia has been shown to be prevalent in the elderly population as well as those with cancer (20, 21). The prevalence of a low SMI in this COVID-19 cohort was \( \sim 50% \) when those with cancer were excluded. If we compare this with cohorts of patients with curative colorectal and advanced lung cancer, similar levels of prevalence of a low SMI are observed (8, 9). This would suggest that sarcopenia is endemic and not

### Table 1 Results of body composition analysis of patients with COVID-19 determined from CT

| Body composition measurement | Frequency, n(%) |
|-----------------------------|-----------------|
| **Obesity**                 |                 |
| High SFI (14): males \( > 60.0 \text{ cm}^2/\text{m}^2 \), females \( > 42.0 \text{ cm}^2/\text{m}^2 \) | No: 16 (25.4); yes: 47 (74.6) |
| Visceral obesity (15, 16): VFA: males \( > 160 \text{ cm}^2 \), females \( > 80 \text{ cm}^2 \) | No: 21 (33.3); yes: 42 (66.7) |
| **Sarcopenia**              |                 |
| SMI (15):                   |                 |
| Males: BMI \( < 25 \text{ kg/m}^2 \) and SMI \( < 43 \text{ cm}^2/\text{m}^2 \), or BMI \( \geq 25 \text{ and SMI} < 53 \text{ cm}^2/\text{m}^2 \) | No: 24 (38.1); yes: 39 (61.9) |
| Females: BMI \( < 25 \text{ and SMI} < 41 \text{ cm}^2/\text{m}^2 \), or BMI \( \geq 25 \text{ and SMI} < 41 \text{ cm}^2/\text{m}^2 \) | No: 24 (38.1); yes: 39 (61.9) |
| **Myosteatosis**            |                 |
| SMD (15): BMI \( < 25 \text{ and SMD} < 41 \text{ HU} \), or BMI \( \geq 25 \text{ and SMD} < 33 \text{ HU} \) | No: 12 (19.0); yes: 51 (81.0) |

1COVID-19, coronavirus disease; CT, computed tomography; HU, Hounsfield units; SFI, subcutaneous fat index; SMD, skeletal muscle radiodensity; SMI, skeletal muscle index; VFA, visceral fat area.
**TABLE 2** Patient characteristics

| Demographics               | Frequency, n (%) |
|----------------------------|------------------|
| **Sex**                    |                  |
| Male                       | 30 (47.6)        |
| Female                     | 33 (52.4)        |
| **Age, y**                 |                  |
| <70                        | 21 (33.3)        |
| ≥70                        | 42 (66.7)        |
| **Ethnicity**              |                  |
| White                      | 59 (93.7)        |
| Other                      | 4 (6.3)          |
| **BMI, kg/m²**             |                  |
| ≥25                        | 31 (49.2)        |
| ≥30                        | 15 (23.8)        |
| **Smoking status**         |                  |
| Current                    | 10 (15.9)        |
| Ex                         | 28 (44.4)        |
| Never                      | 25 (39.7)        |
| **Alcohol excess history** |                  |
| Yes                        | 11 (17.5)        |
| No                         | 52 (82.5)        |
| **Clinical frailty**       |                  |
| Yes                        | 45 (71.4)        |
| No                         | 16 (25.4)        |
| Not recorded               | 2 (3.2)          |
| **Comorbidities**          |                  |
| Liver disease              |                  |
| Yes                        | 6 (9.5)          |
| No                         | 57 (90.5)        |
| Hypertension               |                  |
| Yes                        | 34 (53.1)        |
| No                         | 29 (45.3)        |
| Heart failure              |                  |
| Yes                        | 8 (12.7)         |
| No                         | 55 (87.3)        |
| T2DM                       |                  |
| Yes                        | 18 (28.1)        |
| No                         | 45 (70.3)        |
| Chronic renal failure      |                  |
| Yes                        | 11 (17.5)        |
| No                         | 52 (82.5)        |
| Asthma                     |                  |
| Yes                        | 13 (20.6)        |
| No                         | 50 (79.4)        |
| COPD                       |                  |
| Yes                        | 14 (22.2)        |
| No                         | 49 (77.8)        |
| Active cancer              |                  |
| Yes                        | 11 (17.5)        |
| No                         | 52 (82.5)        |
| CT imaging                 |                  |
| Thorax, abdomen, and pelvis| 48 (76.2)        |
| Abdomen and pelvis only    | 15 (23.8)        |
| **Inflammatory status**    |                  |
| CRP, mg/L                  |                  |
| >10                        | 52 (82.5)        |
| >80                        | 31 (49.2)        |
| ≥150                       | 14 (22.2)        |
| Albumin, g/L               |                  |
| <25                        | 13 (20.6)        |
| ≥25                        | 50 (79.4)        |

(Continued)

**TABLE 2** (Continued)

| Demographics               | Frequency, n (%) |
|----------------------------|------------------|
| NLR                        |                  |
| <3                         | 10 (15.5)        |
| 3–5                        | 12 (18.8)        |
| >5                         | 41 (64.1)        |
| poGPS                      |                  |
| ≥1                         | 41 (65.1)        |
| 1–2                        | 22 (34.9)        |

| Primary outcomes           |                  |
| ITU admission              |                  |
| Yes                        | 3 (4.8)          |
| No                         | 60 (95.2)        |
| 30-d mortality             |                  |
| Yes                        | 11 (17.5)        |
| No                         | 52 (82.5)        |

1 COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; CT, computed tomography; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; T2DM, type 2 diabetes mellitus.

Exclusive to those with COVID-19. This brings into question of how to mitigate the inflammatory effects of COVID-19 in such patients. Clearly, moderation of the systemic inflammatory response could be important, and indeed randomized controlled trials have shown the value of anti-inflammatory agents (22). From the present results it can be speculated that COVID-19 patients with sarcopenia will benefit most from such therapeutic agents.

Systemic inflammation has been shown to be associated with poor outcomes in patients with COVID-19 (23). In addition, several studies have shown the negative impact of an elevated NLR on those with COVID-19 (24, 25). The poGPS is a validated score that is independently associated with infective complications and 30-d mortality in patients undergoing surgery (12). This score was chosen due to the significant degree of inflammation exhibited by those with COVID-19. A similar prevalence of systemic inflammation, as measured by CRP ≥80, poGPS ≥1, and NLR to ≥5, was observed in the present cohort (49%, 36%, and 62%, respectively), and across the entire cohort from which the patients in this study were identified (51%, 25%, and 55%, respectively) (23). Furthermore, when compared with COVID-19 cohorts from further afield, such as the Far East, such systemic inflammation was also prevalent (26). Therefore, activation of the host systemic inflammatory response is a consistent feature of this disease. From the present results it may be speculated that the prognostic value and treatment of the systemic inflammatory response will be greatest in those COVID-19 patients with sarcopenia.

There are a number of limitations of this present study. Importantly, this study is a single-center study with a small sample size and therefore subject to sample bias. Although the present study has a small sample size, it is important to highlight that not all patients with COVID-19 undergo routine CT imaging in the United Kingdom. Within the literature there is a single study with a larger cohort than ours (27). However, they used a nonstandardized methodology for the calculation of SMI (27). Two other smaller studies assessed the relation between VFA and clinical outcomes in those with COVID-19 (6, 7). To our knowledge, the present study has the largest cohort to date exploring the relation between CT body composition measurements, systemic inflammation, and clinical outcomes in patients with COVID-19. Therefore, the
| Clinicopathological characteristic | All, n = 63 | Low VFA, n = 21 (33.3%) | High VFA, n = 42 (66.7%) | P value3 |
|-----------------------------------|-------------|--------------------------|--------------------------|----------|
| Sex                               |             |                          |                          | 0.285    |
| Male                              | 30 (47.6%)  | 12 (57.1%)               | 18 (42.9%)               |          |
| Female                            | 33 (52.4%)  | 9 (42.9%)                | 24 (57.1%)               |          |
| Age, y                            |             |                          |                          | 0.571    |
| <70                               | 21 (33.3%)  | 6 (28.6%)                | 15 (35.7%)               |          |
| ≥70                               | 42 (66.7%)  | 15 (71.4%)               | 27 (64.3%)               |          |
| Ethnicity                         |             |                          |                          | 0.715    |
| White                             | 59 (93.7%)  | 20 (95.2%)               | 39 (92.9%)               |          |
| Other                             | 4 (6.3%)    | 1 (4.8%)                 | 3 (7.1%)                 |          |
| BMI, kg/m²                         |             |                          |                          | 0.003    |
| 25–29                             | 16 (51.6%)  | 3 (14.3%)                | 13 (31.0%)               |          |
| ≥30                               | 15 (48.4%)  | 1 (4.8%)                 | 14 (33.3%)               |          |
| Smoking status                    |             |                          |                          | 0.009    |
| Current                           | 10 (15.9%)  | 7 (33.3%)                | 3 (7.1%)                 |          |
| Ex                                | 28 (44.4%)  | 10 (47.6%)               | 18 (42.9%)               |          |
| Never                             | 25 (39.7%)  | 4 (19.0%)                | 21 (50.0%)               |          |
| Alcohol excess Hx.                |             |                          |                          | 0.241    |
| Yes                               | 11 (17.5%)  | 2 (9.5%)                 | 9 (21.4%)                |          |
| No                                | 52 (82.5%)  | 19 (90.5%)               | 33 (78.6%)               |          |
| Clinical frailty                  |             |                          |                          | 0.356    |
| Yes                               | 45 (71.4%)  | 17 (81.0%)               | 28 (70.0%)               |          |
| No                                | 16 (25.4%)  | 4 (19.0%)                | 12 (30.0%)               |          |
| Liver disease                     |             |                          |                          |          |
| Yes                               | 6 (9.5%)    | 1 (4.8%)                 | 5 (11.9%)                |          |
| No                                | 57 (90.5%)  | 20 (95.2%)               | 37 (88.1%)               | 0.363    |
| Hypertension                      |             |                          |                          | 0.721    |
| Yes                               | 34 (53.1%)  | 12 (57.1%)               | 22 (52.4%)               |          |
| No                                | 29 (45.3%)  | 9 (42.9%)                | 20 (47.6%)               |          |
| Heart failure                     |             |                          |                          | 0.539    |
| Yes                               | 8 (12.7%)   | 2 (9.5%)                 | 6 (14.3%)                |          |
| No                                | 55 (87.3%)  | 19 (90.5%)               | 36 (85.7%)               |          |
| T2DM                              |             |                          |                          | 0.076    |
| Yes                               | 18 (28.1%)  | 3 (14.3%)                | 15 (35.7%)               |          |
| No                                | 45 (70.3%)  | 18 (85.7%)               | 27 (64.3%)               |          |
| Chronic renal failure             |             |                          |                          | 0.348    |
| Yes                               | 11 (17.5%)  | 5 (23.8%)                | 6 (14.3%)                |          |
| No                                | 52 (82.5%)  | 16 (76.2%)               | 36 (85.7%)               |          |
| Asthma                            |             |                          |                          | 0.123    |
| Yes                               | 13 (20.6%)  | 2 (9.5%)                 | 11 (26.2%)               |          |
| No                                | 50 (79.4%)  | 19 (90.5%)               | 31 (73.8%)               |          |
| COPD                              |             |                          |                          | 0.391    |
| Yes                               | 14 (22.2%)  | 6 (28.6%)                | 8 (19.0%)                |          |
| No                                | 49 (77.8%)  | 15 (71.4%)               | 34 (81.0%)               |          |
| Active cancer                     |             |                          |                          | 0.019    |
| Yes                               | 11 (17.5%)  | 7 (33.3%)                | 4 (9.5%)                 |          |
| No                                | 52 (82.5%)  | 14 (66.7%)               | 38 (80.5%)               | 0.188    |
| CRP, mg/L                         |             |                          |                          |          |
| ≥10                               | 52 (82.5%)  | 8 (26.8%)                | 21 (42.9%)               |          |
| ≥80                               | 31 (49.2%)  | 7 (33.3%)                | 22 (42.2%)               |          |
| ≥150                              | 14 (22.2%)  | 8 (38.1%)                | 14 (33.3%)               |          |
| Albumin, g/L                      |             |                          |                          | 0.271    |
| <25                               | 13 (20.6%)  | 6 (28.6%)                | 7 (16.7%)                |          |
| ≥25                               | 50 (79.4%)  | 15 (71.4%)               | 35 (83.3%)               |          |
| NLR                               |             |                          |                          | 0.132    |
| <3                                | 10 (15.6%)  | 1 (4.8%)                 | 9 (21.4%)                |          |
| 3–5                               | 12 (18.8%)  | 3 (14.3%)                | 9 (21.4%)                |          |
| >5                                | 41 (64.1%)  | 17 (81.0%)               | 24 (57.1%)               |          |
| poGPS                             |             |                          |                          | 0.350    |
| 0                                 | 41 (65.1%)  | 12 (57.1%)               | 29 (69.0%)               |          |
| 1–2                               | 22 (34.9%)  | 9 (42.9%)                | 13 (31.0%)               | 0.012    |
| ITU admission                     |             |                          |                          |          |
| Yes                               | 3 (4.8%)    | 3 (14.3%)                | 0 (0%)                   |          |
| No                                | 60 (95.2%)  | 18 (85.7%)               | 42 (100%)                |          |
| 30-d mortality                    |             |                          |                          | 0.002    |
| Yes                               | 11 (17.5%)  | 8 (38.1%)                | 3 (7.1%)                 |          |
| No                                | 52 (82.5%)  | 13 (61.9%)               | 39 (92.9%)               |          |

1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; T2DM, type 2 diabetes mellitus; VFA, visceral fat area.

2High VFA defined as >160 cm² for males and >80 cm² for females.

3P value is from χ² analysis.
| Clinicopathological characteristic | All, \( n = 63 \) | Low SFI, \( n = 16 \) (25.4%) | High SFI, \( n = 47 \) (74.6%) | \( P \) value\(^3\) |
|-----------------------------------|-----------------|------------------|-----------------|------------------|
| **Sex**                           |                 |                  |                 |
| Male                              | 30 (47.6)       | 11 (68.8)        | 19 (40.4)       | 0.050            |
| Female                            | 33 (52.4)       | 5 (31.3)         | 28 (59.6)       |                  |
| **Age, y**                        |                 |                  |                 |
| <70                               | 21 (33.3)       | 1 (6.2)          | 20 (42.6)       | 0.008            |
| \( \geq 70 \)                     | 42 (66.7)       | 15 (93.8)        | 27 (57.4)       |                  |
| **Ethnicity**                     |                 |                  |                 |
| White                             | 59 (93.7)       | 16 (100)         | 43 (91.5)       | 0.228            |
| Other                             | 4 (6.3)         | 0 (0)            | 4 (8.5)         |                  |
| **BMI, kg/m\(^2\)**              |                 |                  |                 |
| 25–29                             | 16 (51.6)       | 2 (12.5)         | 14 (29.8)       | 0.002            |
| \(\geq 30\)                       | 15 (48.4)       | 0 (0)            | 15 (31.5)       |                  |
| **Smoking status**                |                 |                  |                 |
| Current                           | 10 (15.9)       | 5 (31.3)         | 5 (10.6)        | 0.113            |
| Ex                                | 28 (44.4)       | 7 (43.8)         | 21 (44.7)       |                  |
| Never                             | 25 (39.7)       | 4 (25.0)         | 21 (44.7)       |                  |
| **Alcohol excess Hx.**            |                 |                  |                 |
| Yes                               | 6 (9.5)         | 0 (0)            | 6 (12.8)        | 0.171            |
| No                                | 57 (90.5)       | 16 (100)         | 41 (87.2)       |                  |
| **Hypertension**                  |                 |                  |                 |
| Yes                               | 34 (53.1)       | 9 (56.3)         | 25 (53.2)       | 0.832            |
| No                                | 29 (45.3)       | 7 (43.8)         | 22 (46.8)       |                  |
| **Heart failure**                 |                 |                  |                 |
| Yes                               | 8 (12.7)        | 4 (25.0)         | 4 (8.5)         | 0.087            |
| No                                | 55 (87.3)       | 12 (75.0)        | 43 (81.5)       |                  |
| **T2DM**                          |                 |                  |                 |
| Yes                               | 18 (28.1)       | 3 (18.8)         | 15 (31.9)       | 0.314            |
| No                                | 45 (70.3)       | 13 (81.3)        | 32 (63.8)       |                  |
| **Chronic renal failure**         |                 |                  |                 |
| Yes                               | 11 (17.5)       | 6 (37.5)         | 5 (10.6)        | 0.014            |
| No                                | 52 (82.5)       | 10 (62.5)        | 42 (89.4)       |                  |
| **Asthma**                        |                 |                  |                 |
| Yes                               | 13 (20.6)       | 0 (0)            | 13 (27.7)       | 0.018            |
| No                                | 50 (79.4)       | 16 (100)         | 34 (72.3)       |                  |
| **COPD**                          |                 |                  |                 |
| Yes                               | 14 (22.2)       | 4 (25.0)         | 10 (21.3)       | 0.757            |
| No                                | 49 (77.8)       | 12 (75.0)        | 37 (78.7)       |                  |
| **Active cancer**                 |                 |                  |                 |
| Yes                               | 11 (17.5)       | 6 (37.5)         | 5 (10.6)        | 0.014            |
| No                                | 52 (82.5)       | 10 (62.5)        | 42 (89.4)       |                  |
| **CRP, mg/L**                     |                 |                  |                 |
| \(\geq 10\)                       | 52 (82.5)       | 7 (43.8)         | 15 (38.5)       | 0.498            |
| \(\geq 60\)                       | 31 (49.2)       | 5 (31.3)         | 10 (25.6)       |                  |
| \(\geq 150\)                      | 14 (22.2)       | 4 (25.0)         | 14 (29.5)       |                  |
| **Albumin, g/L**                  |                 |                  |                 |
| \(< 25\)                          | 13 (20.6)       | 3 (18.8)         | 10 (21.3)       | 0.829            |
| \(\geq 25\)                       | 50 (79.4)       | 13 (81.3)        | 37 (78.7)       |                  |
| **NLR**                           |                 |                  |                 |
| \(< 3\)                           | 10 (15.6)       | 2 (12.5)         | 8 (17.0)        | 0.905            |
| \(3–5\)                           | 12 (18.8)       | 3 (18.8)         | 9 (19.1)        |                  |
| \(> 5\)                           | 41 (64.1)       | 11 (68.8)        | 30 (63.8)       |                  |
| **poGPS**                         |                 |                  |                 |
| 0                                 | 41 (65.1)       | 13 (81.3)        | 28 (59.6)       | 0.116            |
| 1–2                               | 22 (34.9)       | 3 (18.8)         | 19 (40.4)       |                  |
| **ITU admission**                 |                 |                  |                 |
| Yes                               | 3 (4.8)         | 1 (6.2)          | 2 (4.3)         | 0.746            |
| No                                | 60 (95.2)       | 15 (93.8)        | 45 (95.7)       |                  |
| **30-dmortality**                 |                 |                  |                 |
| Yes                               | 11 (17.5)       | 5 (31.3)         | 6 (12.8)        | 0.093            |
| No                                | 52 (82.5)       | 11 (68.8)        | 41 (87.2)       |                  |

\(^1\)Values are \( n \) (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; SFI, subcutaneous fat index; T2DM, type 2 diabetes mellitus.

\(^2\)High SFI defined as \( >50.0 \text{ cm}^2/\text{m}^2 \) for males and \( >42.0 \text{ cm}^2/\text{m}^2 \) for females.

\(^3\)\( P \) value is from \( \chi^2 \) analysis.
| Clinicopathological characteristic | All, \( n = 63 \) | Normal/high SMI, \( n = 24 \) (38.1%) | Low SMI, \( n = 39 \) (61.9%) | \( P \) value$^3$ |
|-----------------------------------|----------------|---------------------------------|--------------------------------|----------------|
| Sex                               |                |                                |                               | 0.824          |
| Male                              | 30(47.6)       | 11(45.8)                       | 19(48.7)                      |                |
| Female                            | 33(52.4)       | 13(54.2)                       | 20(51.3)                      |                |
| Age, y                            |                |                                |                               | 0.271          |
| <70                               | 21(33.3)       | 10(41.7)                       | 11(28.2)                      |                |
| ≥70                               | 42(66.7)       | 14(58.3)                       | 28(71.8)                      |                |
| Ethnicity                         |                |                                |                               | 0.577          |
| White                             | 50(93.7)       | 23(95.8)                       | 36(92.3)                      |                |
| Other                             | 4(6.3)         | 1(4.2)                         | 3(7.7)                        |                |
| BMI, kg/m$^2$                     |                |                                |                               | 0.003          |
| 25–29                             | 16(51.6)       | 3(14.3)                        | 13(31.0)                      |                |
| ≥30                               | 15(48.4)       | 1(4.8)                         | 14(33.3)                      |                |
| Smoking status                    |                |                                |                               | 0.182          |
| Current                           | 10(15.9)       | 3(12.5)                        | 7(17.9)                       |                |
| Ex                                | 28(44.4)       | 8(33.3)                        | 20(51.3)                      |                |
| Never                             | 25(39.7)       | 13(54.2)                       | 12(30.8)                      |                |
| Alcohol excess Hx.                |                |                                |                               | 0.216          |
| Yes                               | 11(17.5)       | 6(25.0)                        | 5(12.8)                       |                |
| No                                | 52(82.5)       | 18(75.0)                       | 34(87.2)                      |                |
| Clinical frailty                  |                |                                |                               | 0.177          |
| Yes                               | 45(71.4)       | 14(63.6)                       | 31(79.5)                      |                |
| No                                | 16(25.4)       | 8(36.4)                        | 8(20.5)                       |                |
| Liver disease                     |                |                                |                               | 0.130          |
| Yes                               | 6(9.5)         | 4(16.7)                        | 2(5.1)                        |                |
| No                                | 57(90.5)       | 20(83.3)                       | 37(94.9)                      |                |
| Hypertension                      |                |                                |                               | 0.980          |
| Yes                               | 34(53.1)       | 13(54.2)                       | 21(53.8)                      |                |
| No                                | 29(45.9)       | 11(45.8)                       | 18(46.2)                      |                |
| Heart failure                     |                |                                |                               | 0.128          |
| Yes                               | 8(12.7)        | 5(20.8)                        | 3(7.7)                        |                |
| No                                | 55(87.3)       | 19(79.2)                       | 36(92.3)                      |                |
| T2DM                              |                |                                |                               | 0.623          |
| Yes                               | 18(28.1)       | 6(25.0)                        | 12(30.8)                      |                |
| No                                | 45(71.9)       | 18(75.0)                       | 27(69.2)                      |                |
| Chronic renal failure             |                |                                |                               | 0.216          |
| Yes                               | 11(17.5)       | 6(25.0)                        | 11(27.5)                      |                |
| No                                | 52(82.5)       | 18(75.0)                       | 42(72.5)                      |                |
| Asthma                            |                |                                |                               | 0.976          |
| Yes                               | 13(20.6)       | 5(20.8)                        | 8(20.5)                       |                |
| No                                | 50(79.4)       | 19(79.2)                       | 31(79.5)                      |                |
| COPD                              |                |                                |                               | 0.677          |
| Yes                               | 14(22.2)       | 6(25.0)                        | 8(20.5)                       |                |
| No                                | 49(77.8)       | 18(75.0)                       | 31(79.5)                      |                |
| Active cancer                     |                |                                |                               | 0.896          |
| Yes                               | 11(17.5)       | 4(16.7)                        | 7(17.9)                       |                |
| No                                | 52(82.5)       | 20(83.3)                       | 32(82.1)                      |                |
| CRP, mg/L                         |                |                                |                               | 0.598          |
| ≥10                               | 52(82.5)       | 12(50.0)                       | 15(38.5)                      |                |
| ≥80                               | 31(49.2)       | 4(16.7)                        | 10(25.6)                      |                |
| ≥150                              | 14(22.2)       | 8(33.3)                        | 14(35.9)                      |                |
| Albumin, g/L                      |                |                                |                               | 0.541          |
| <25                               | 13(20.6)       | 4(16.7)                        | 9(23.1)                       |                |
| ≥25                               | 50(78.4)       | 20(83.3)                       | 30(76.9)                      |                |
| NLR                               |                |                                |                               | 0.245          |
| <3                                | 10(15.6)       | 6(25.0)                        | 4(10.3)                       |                |
| 3–5                               | 12(18.8)       | 5(20.8)                        | 7(17.9)                       |                |
| >5                                | 41(64.1)       | 13(54.2)                       | 28(73.5)                      |                |
| poGPS                             |                |                                |                               | 0.452          |
| 0                                 | 41(65.1)       | 7(29.2)                        | 15(38.5)                      |                |
| 1–2                               | 22(34.9)       | 17(60.7)                       | 24(61.5)                      |                |
| ITU admission                     |                |                                |                               | 0.862          |
| Yes                               | 3(4.8)         | 1(4.2)                         | 2(5.1)                        |                |
| No                                | 60(95.2)       | 23(95.8)                       | 37(94.9)                      |                |
| 30-d mortality                    |                |                                |                               | 0.029          |
| Yes                               | 11(17.5)       | 1(4.2)                         | 10(25.6)                      |                |
| No                                | 52(82.5)       | 23(95.8)                       | 29(74.4)                      |                |

$^1$Values are \( n \) (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; SMI, skeletal muscle index; T2DM, type 2 diabetes mellitus.

$^2$Low SMI defined as BMI <25 kg/m$^2$ and SMI <43 cm$^2$/m$^2$, or BMI ≥25 and SMI <53 cm$^2$/m$^2$ for males; and BMI <25 and SMI <41 cm$^2$/m$^2$, or BMI ≥25 and SMI <41 cm$^2$/m$^2$ for females.

$^3$\( P \) value is from \( \chi^2 \) analysis.
| Clinicopathological characteristic | All, n = 63 | Normal/high SMD, n = 12 (19.0%) | Low SMD, n = 51 (81.0%) | P-value |
|-----------------------------------|------------|---------------------------------|------------------------|---------|
| Sex | | | | 0.035 |
| Male | 30 (47.6) | 9 (75.0) | 21 (41.2) | |
| Female | 33 (52.4) | 3 (25.0) | 30 (58.8) | |
| Age, y | | | | 0.173 |
| <70 | 21 (33.3) | 6 (50.0) | 15 (29.4) | |
| ≥70 | 42 (66.7) | 6 (50.0) | 36 (70.6) | |
| Ethnicity | | | | 0.316 |
| White | 59 (93.7) | 12 (100.0) | 47 (92.2) | |
| Other | 4 (6.3) | 0 (0) | 4 (7.8) | |
| BMI, kg/m² | | | | <0.001 |
| 25–29 | 16 (51.6) | 10 (83.3) | 6 (11.8) | |
| >30 | 15 (48.4) | 2 (16.7) | 13 (25.5) | |
| Smoking status | | | | 0.878 |
| Current | 10 (15.9) | 2 (16.7) | 8 (15.7) | |
| Ex | 28 (44.4) | 6 (50.0) | 22 (43.1) | |
| Never | 25 (39.7) | 4 (33.3) | 21 (41.2) | |
| Alcohol excess Hx. | | | | 0.107 |
| Yes | 11 (17.5) | 4 (33.3) | 7 (13.7) | |
| No | 52 (82.5) | 8 (66.7) | 44 (86.3) | |
| Clinical frailty | | | | 0.175 |
| Yes | 45 (71.4) | 7 (58.3) | 38 (77.6) | |
| No | 16 (25.4) | 5 (41.7) | 11 (22.4) | |
| Liver disease | | | | 0.876 |
| Yes | 5 (8.3) | 1 (8.3) | 5 (9.8) | |
| No | 57 (91.7) | 11 (91.7) | 46 (90.2) | |
| Hypertension | | | | 0.759 |
| Yes | 34 (53.1) | 6 (50.0) | 28 (54.9) | |
| No | 29 (45.9) | 6 (50.0) | 23 (45.1) | |
| Heart failure | | | | 0.614 |
| Yes | 11 (17.5) | 1 (8.3) | 7 (13.7) | |
| No | 52 (82.5) | 11 (91.7) | 41 (80.4) | |
| T2DM | | | | 0.685 |
| Yes | 18 (28.1) | 4 (33.3) | 14 (27.5) | |
| No | 45 (70.3) | 8 (66.7) | 37 (72.5) | |
| Chronic renal failure | | | | 0.355 |
| Yes | 11 (17.5) | 1 (8.3) | 10 (19.6) | |
| No | 52 (82.5) | 11 (91.7) | 41 (80.4) | |
| Asthma | | | | 0.242 |
| Yes | 13 (20.6) | 1 (8.3) | 12 (23.5) | |
| No | 50 (79.4) | 11 (91.7) | 39 (76.5) | |
| COPD | | | | 0.607 |
| Yes | 14 (22.2) | 2 (16.7) | 12 (23.5) | |
| No | 49 (77.8) | 10 (83.3) | 39 (76.5) | |
| Active cancer | | | | 0.355 |
| Yes | 11 (17.5) | 1 (8.3) | 10 (19.6) | |
| No | 52 (82.5) | 11 (91.7) | 41 (80.4) | |
| CRP, mg/L | | | | 0.817 |
| ≥10 | 52 (82.5) | 5 (41.7) | 22 (43.1) | |
| ≥60 | 31 (49.2) | 2 (16.7) | 12 (23.5) | |
| ≥150 | 14 (22.2) | 5 (41.7) | 17 (33.3) | |
| Albumin, g/L | | | | 0.242 |
| <25 | 13 (20.6) | 1 (8.3) | 12 (23.5) | |
| ≥25 | 50 (79.4) | 11 (91.7) | 39 (76.5) | |
| NLR | | | | 0.456 |
| <3 | 10 (15.6) | 3 (25.0) | 7 (13.7) | |
| 3–5 | 12 (18.8) | 3 (25.0) | 9 (17.6) | |
| >5 | 41 (64.1) | 6 (50.0) | 35 (68.6) | |
| poGPS | | | | 0.898 |
| 0 | 41 (65.1) | 8 (66.7) | 23 (45.1) | |
| 1–2 | 22 (34.9) | 4 (33.3) | 18 (35.3) | |
| ITU admission | | | | 0.518 |
| Yes | 3 (4.8) | 1 (8.3) | 2 (3.9) | |
| No | 60 (95.2) | 11 (91.7) | 49 (96.1) | |
| 30-dmortality | | | | 0.355 |
| Yes | 11 (17.5) | 1 (8.3) | 11 (17.5) | |
| No | 52 (82.5) | 11 (91.7) | 52 (82.5) | |

1Values are n (%). COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease; CRP, C-reactive protein; HU, Hounsfield unit; Hx., history; ITU, intensive therapy or care unit; NLR, neutrophil:lymphocyte ratio; poGPS, perioperative Glasgow Prognostic Score; SMD, skeletal muscle radiodensity; T2DM, type 2 diabetes mellitus.
2Low SMD defined as BMI <25 kg/m² and SMD <41 HU, or BMI ≥25 and SMD <33 HU for both sexes.
3P-value is from χ² analysis.
Data described in the manuscript will be made available upon request pending application and approval of the senior author.

References

1. Organization WH, WHO Director-General’s opening remarks at the media briefing on COVID-19 2020 [accessed 1st Feb 2021].

2. GOV.UK. Coronavirus (COVID-19) in the UK. UK summary [Internet]. [cited 1st Feb 2021]. Available from: https://www.gov.uk/government/collections/coronavirus-covid-19-in-the-uk

3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223): 497–506.

4. Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest 2020;80(6):441–7.

5. Deng M, Qi Y, Deng L, Wang H, Xu Y, Li Z, Meng Z, Tang J, Dai Z. Obesity as a potential predictor of disease severity in young COVID-19 patients: a retrospective study. Obesity (Silver Spring) 2020;28(10):1815–25.

6. Petersen A, Bressem K, Allbrecht J, Thieß HM, Vahlidiek J, Hamb B, Makowski MR, Niehues A, Niehues SM, Adams LC. The role of visceral adiposity in the severity of COVID-19: highlights from a unicenter cross-sectional pilot study in Germany. Metabolism 2020;110:154317.

7. Yang Y, Ding L, Zou X, Shen Y, Hu D, Hu X, Li Z, Kamel IR. Visceral adiposity and high intramuscular fat deposition independently predict critical illness in patients with SARS-CoV-2. Obesity (Silver Spring) 2020;28(11):2040–8.

8. Abbas T, Dolan RD, Laird BJ, McMillan DC. The relationship between imaging-based body composition analysis and the systemic inflammatory response in patients with cancer: a systematic review. Cancers (Basel) 2019;11(9):1304.

9. Dolan RD, Almasaud AS, Dieu LB, Horgan PG, McSorley ST, McMillan DC. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. J Cachexia Sarcopenia Muscle 2019;10(1):111–22.

10. Health Protection Scotland. Coronavirus (COVID-19) [Internet]. [cited 1st Feb 2021]. Available from: https://www.hps.scot.nhs.uk/a-to-z-of-topics/covid-19/

11. Zahores R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratsol Lek Listy 2001;102:5–14.

12. Watt DG, McSorley ST, Park JH, Horgan PG, McMillan DC. A postoperative systemic inflammation score predicts short- and long-term outcomes in patients undergoing surgery for colorectal cancer. Ann Surg Oncol 2017;24(4):1100–9.

13. Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, Xiao J, Alexeef S, Corley D, Weltzien E, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol 2017;3(12):e172319.

14. Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, Mazurak VC. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer 2017;117(1):148–55.

15. Martin L, Birdsell L, Macdonald N, Reiman T, Cladinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31(12):1539–47.

16. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9(7): 629–35.

17. Kwok S, Adam S, Ho JH, Iqbal Z, Turckington P, Razvi S, Le Roux CW, Soran H, Syed AA. Obesity: a critical risk factor in the COVID-19 pandemic. Clin Obes 2020;10(6):e12403.

18. Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011;364(14):1293–304.

19. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15(11):e493–503.

20. Broughman JR, Williams GR, Deal AM, Yu H, Nyrop KA, Alston SM, Gordon BB, Sanoff HK, Muss HB. Prevalence of sarcopenia in older patients with colorectal cancer. J Geriatr Oncol 2015;6(6): 442–5.

21. Duong RF, Roussel B, Kulakova E, Pandya C, Fleming FJ, Hensley M, Magnuson AM, Loh KP, Gilles M, Ramsdale E, et al. Characterizing cancer cachexia in the geriatric oncology population. J Geriatr Oncol 2019;10(3):415–19.

22. Rello J, Waterer GW, Bourdoli A, Roquilly A. COVID-19, steroids and other immunomodulators: the jigsaw is not complete. Anaesth Crit Care 2020;84:106504.

23. Maguire D, Woods M, Richards C, Dolan R, Veitch JW, Sim WMJ, Kwan ML, Xiao J, Corley D, Weltzien E, et al. Neutrophil-to-lymphocyte ratio predicts critical illness and d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504.

24. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504.

25. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020;18(1):354.

26. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Hu Y, Wang H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1094.

27. Mocetezuma-Velázquez P, Miranda-Zazueta G, Ortiz-Brizuela E, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Díaz-Mejía BA, Pérez-Garcia E, Villanueva-Reza M, Tovar-Méndez VH, et al. Low thoracic skeletal muscle area is not associated with negative outcomes in patients with COVID-19. Am J Phys Med Rehabil 2021;100(5):413–18.